Published: 2018-07-25

Role of dutasteride (5-alpha-reductase inhibitor) in patients undergoing transurethral resection of prostrate

Shafeen Majid Koul, Imtiaz Shah, Omer Khurshid, Shehwar Majid Koul, Momin Shah


Background: Bladder outflow obstruction due to benign prostate hyperplasia is the commonest urological condition affecting men over 50 years of age. Medical therapy is usually the first line management of BPH. The most frequent complication is encountered is perioperative bleeding and postoperative bleeding. Preoperative use of 5-alpha-reductase inhibitors like dutasteride to reduce surgical bleeding is still a topic of debate. The aim of this study was to evaluate whether pretreatment with dutasteride for 4 weeks prior to surgery can reduce surgical blood loss as well as post op blood loss and complications.

Methods: A total of 60 patients with BHP who were to undergo TURP were enrolled and randomized into 2 groups. The dutasteride group consisted of 30 patients who were treated with dutasteride (0.5mg) for 4 weeks before surgery and the control group consisted of 30 patients.

Results: The preoperative hemoglobin levels of cases and controls was done followed by postoperative hemoglobin. The average fall in hemoglobin was 0.9mg/dl in cases and 2.1mg/dl in controls. Concluding that group of patients taking dutasteride (cases) peri and post-operative surgical bleeding was significantly reduced on pretreatment of dutasteride for 4 weeks before TURP.

Conclusions: Many other surgical treatments are being developed for BHP, but TURP is the gold standard treatment. However, morbidity and blood loss are major potential complications and taking dutasteride 4 weeks prior to transurethral resection of prostrate can be effective in reducing its complications.


Benign prostratic hyperplasia, Bleeding, Dutasteride, TURP

Full Text:



Andriole G, Bruchovsky N, Chung LW, Matsumoto AM, Rittmaster R, Roehrborn C, et al. Dihydrotestosterone and the prostate: the scientific rationale for 5α-reductase inhibitors in the treatment of benign prostatic hyperplasia. J urology. 2004 Oct 1;172(4):1399-403.

Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Meta. 2004;89(5):2179-84.

Keam SJ, Scott LJ. Dutasteride: a review of its use in the management of prostate disorders. Drugs. 2008;68(4):463-85.

Bramson HN, Hermann D, Batchelor KW, Lee FW, James MK, Frye SV. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharmacology and Experimental Therapeutics. 1997;282(3):1496-502.

Frye SV. Discovery and clinical development of dutasteride, a potent dual 5α-reductase inhibitor. Current Topics in Medicinal Chemistry. 2006;6(5):405-21.

Marberger M. Drug insight: 5α-reductase inhibitors for the treatment of benign prostatic hyperplasia. Nature Clinical Practice Urology. 2006;3(9):495-503.

Martov AG, Ergakov DV. The experience in dutasteride use before transurethral prostatic resection for large adenoma. Urologiia. 2008;(4):46.

Woo JH, Kang JY, Kim EK, Yoo TK. The effect of short term dutasteride therapy on microvessel density in benign prostatic hyperplasia. Korean J Urol. 2008;49:515-9.

Kravchick S, Cytron S, Mamonov A, Peled R, Linov L. Effect of short-term dutasteride therapy on prostate vascularity in patients with benign prostatic hyperplasia: a pilot study. Urology. 2009;73(6):1274-8.

Hahn RG, Fagerström T, Tammela TL, Van Vierssen Trip O, Beisland HO, Duggan A, et al. Blood loss and postoperative complications associated with transurethral resection of the prostate after pretreatment with dutasteride. BJU international. 2007 Mar;99(3):587-94.

Zaitsu M, Tonooka A, Mikami K, Hattori M, Takeshima Y, Uekusa T, et al. A dual 5α-reductase inhibitor dutasteride caused reductions in vascular density and area in benign prostatic hyperplasia. ISRN Urol. 2013;2013:863489.

Kim KS, Jeong WS, Park SY, Kim YT, Moon HS. The effect of two weeks of treatment with dutasteride on bleeding after transurethral resection of the prostate. World J Men’s Health. 2015;33(1):14-9.

Pastore AL, Mariani S, Barrese F, Palleschi G, Valentini AM, Pacini L, et al. Transurethral resection of prostate and the role of pharmacological treatment with dutasteride in decreasing surgical blood loss. J Endourol. 2013;27:68-70.